General information, not legal or regulatory advice. Sources were checked on 28 September 2026. bioaccess® does not run studies in Moldova and is not affiliated with any company named here.
Moldova sometimes comes up when MedTech founders look for fast, lower-cost geographies for a first-in-human (FIH) or early feasibility study (EFS). This page summarizes Moldova’s device clinical-investigation rules as its regulator publishes them, gives an honest picture of the country’s device-trial footprint, and compares it with a Latin American start.
The pathway, in the regulator’s own words
A page on the website of Moldova’s Medicines and Medical Devices Agency (AMDM) sets out the legal rules for clinical investigations of medical devices. In summary:
- Devices without CE marking (the European conformity mark) may be supplied for clinical investigation if they meet the applicable technical regulation and come with the manufacturer’s declaration of conformity.
- Applicant: the manufacturer or its authorized representative.
- Before starting, the applicant notifies the Agency. The application must include device data, the clinical investigation plan, and a positive opinion from the National Ethics Committee, plus any other documents the Agency specifies.
- The Agency issues its opinion within 30 working days of receiving a complete application.
- During the investigation: device-related complications must be reported to the Agency within 7 working days. A notified modification may be implemented if the Agency issues no negative decision within 30 working days.
- After completion: the applicant informs the Agency within 30 working days and submits the final report.
That Agency page also carries older news items, so confirm with local counsel that the text reflects the current law and implementing rules.
What is published about timelines
The one official figure is the 30 working days for the Agency’s opinion after a complete application. National ethics review comes before it, since the ethics opinion is part of the application. Ask for a calendar that covers both steps.
Standards and U.S. data acceptance
The U.S. Food and Drug Administration (FDA) accepts device data from outside the United States under 21 CFR 812.28 when the study is well designed and well conducted under good clinical practice (GCP), with independent ethics review and informed consent, and FDA can validate the data. The data can support an investigational device exemption (IDE), 510(k), De Novo or premarket approval (PMA) submission. Run the study to ISO 14155, the international GCP standard for device investigations.
Patients, sites and device experience
- Population: about 2.4 million (World Bank, 2024).
- ClinicalTrials.gov (28 September 2026): only 3 interventional device records list a site in Moldova, and none has “device feasibility” as its primary purpose.
- Moldova does not appear on Clinical Accelerator’s public coverage map. See our regional comparison.
Recruitment reality: a small population and a thin device-trial record mean you would probably rely on very few centers and investigators. Strict inclusion criteria can shrink the eligible pool quickly. Get screening numbers for your criteria and confirm hands-on experience with similar devices before you commit.
Logistics from the United States
- Time zone: Chișinău is on UTC+2 (Coordinated Universal Time plus two hours) in winter and UTC+3 in summer, about 7 hours ahead of U.S. Eastern time.
- Language: Romanian. Confirm the translation requirements for the plan and the informed consent form (ICF).
- Check the U.S. Department of State travel advisory and current routings.
Genuine strengths
Moldova has a short, legislated regulator clock of 30 working days after a complete application, a single national ethics committee, and rules that reference CE marking and link to European Commission device guidance. For a very focused study with a committed local investigator, those are real advantages.
How Latin America compares
- Same FDA rule: 21 CFR 812.28.
- Device-trial footprint: on ClinicalTrials.gov, Panama has 39 interventional device records, Chile 199 and Brazil 1,170.
- Published clocks: our Panama hub publishes 3–5 week ethics approval and a 6–8 week average to first patient with bioaccess® coordination. Argentina’s ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) regulates device clinical investigations under Disposition 969/1997.
- Time zone: 0–2 hours from U.S. Eastern.
- U.S. continuity: bioaccess® is headquartered in Miami, and its sister organization Amavita Research Services runs a Miami device and early feasibility study site.
- Trade-offs: Spanish or Portuguese documents and investigational import permits. Small Latin American countries carry the same narrow-pool risk.
Other country guides: Georgia · Uzbekistan · Kazakhstan · Armenia · Ukraine · Serbia
Frequently asked questions
Who authorizes device clinical investigations in Moldova?
The Medicines and Medical Devices Agency (AMDM) does. A positive opinion from the National Ethics Committee must be included with the application.
How long does the Agency take?
According to the legal text on the Agency’s website, it issues its opinion within 30 working days of receiving a complete application.
Can I use a device without CE marking?
According to the Agency’s page, yes, if it meets the applicable technical regulation and comes with the manufacturer’s declaration of conformity.
Will the FDA accept data from Moldova?
It can. Under 21 CFR 812.28, FDA accepts data from outside the United States from studies run under GCP that it can validate. The decision is made case by case.
Next step
Comparing Moldova with a Latin American start? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.